PL363239A1 - Silensed anti-cd28 antibodies and use thereof - Google Patents

Silensed anti-cd28 antibodies and use thereof

Info

Publication number
PL363239A1
PL363239A1 PL01363239A PL36323901A PL363239A1 PL 363239 A1 PL363239 A1 PL 363239A1 PL 01363239 A PL01363239 A PL 01363239A PL 36323901 A PL36323901 A PL 36323901A PL 363239 A1 PL363239 A1 PL 363239A1
Authority
PL
Poland
Prior art keywords
silensed
antibodies
silensed anti
Prior art date
Application number
PL01363239A
Other languages
Polish (pl)
Inventor
Yun J. Tso
Paul Hinton
Maximiliano Vasouez
Kouichi Tamura
Yasuyuki Higasji
Nobuo Seki
Hirotsugu Ueda
Original Assignee
Fuijsawa Pharmaceutical Co, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuijsawa Pharmaceutical Co, Ltd. filed Critical Fuijsawa Pharmaceutical Co, Ltd.
Publication of PL363239A1 publication Critical patent/PL363239A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL01363239A 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof PL363239A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14

Publications (1)

Publication Number Publication Date
PL363239A1 true PL363239A1 (en) 2004-11-15

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01363239A PL363239A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Country Status (18)

Country Link
EP (1) EP1341553A4 (en)
JP (1) JP2004515243A (en)
KR (1) KR20040020866A (en)
CN (1) CN1272345C (en)
AR (1) AR031924A1 (en)
AU (2) AU2608602A (en)
BR (1) BR0116686A (en)
CA (1) CA2432736A1 (en)
CZ (1) CZ20031909A3 (en)
HU (1) HUP0400697A3 (en)
IL (1) IL156262A0 (en)
MX (1) MXPA03005327A (en)
NO (1) NO20032542L (en)
NZ (1) NZ526569A (en)
PL (1) PL363239A1 (en)
RU (1) RU2261723C2 (en)
WO (1) WO2002047721A1 (en)
ZA (1) ZA200305384B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
FR2951176A1 (en) * 2009-10-09 2011-04-15 Tcl Pharma MONOVALENT LIGANDS OF THE HUMAN CD28 RECEPTOR
PL2536764T3 (en) * 2010-02-18 2018-12-31 Ose Immunotherapeutics Anti-cd28 humanized antibodies
CN114917185B (en) 2016-10-21 2023-11-14 美国安进公司 Pharmaceutical formulations and methods of making the same
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CN113692286A (en) * 2019-03-14 2021-11-23 比昂生物制剂公司 A method for immunosuppression
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023532339A (en) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Viruses engineered to promote sanotransmission and their use in treating cancer
KR20230166150A (en) 2020-08-19 2023-12-06 젠코어 인코포레이티드 Anti-cd28 compositions
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024148336A1 (en) * 2023-01-06 2024-07-11 Igm Biosciences, Inc. T cell costimulatory multimeric binding molecules and uses thereof
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein

Also Published As

Publication number Publication date
MXPA03005327A (en) 2004-12-03
CN1489473A (en) 2004-04-14
ZA200305384B (en) 2004-10-11
HUP0400697A3 (en) 2007-05-02
AU2608602A (en) 2002-06-24
RU2003121231A (en) 2005-02-10
WO2002047721A1 (en) 2002-06-20
JP2004515243A (en) 2004-05-27
CN1272345C (en) 2006-08-30
EP1341553A4 (en) 2004-07-28
IL156262A0 (en) 2004-01-04
AU2002226086B2 (en) 2005-08-25
CZ20031909A3 (en) 2003-11-12
NO20032542L (en) 2003-08-07
EP1341553A1 (en) 2003-09-10
NO20032542D0 (en) 2003-06-05
BR0116686A (en) 2003-12-30
CA2432736A1 (en) 2002-06-20
HUP0400697A2 (en) 2004-06-28
AU2002226086C1 (en) 2006-03-09
AR031924A1 (en) 2003-10-08
KR20040020866A (en) 2004-03-09
RU2261723C2 (en) 2005-10-10
NZ526569A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
HK1208705A1 (en) Multivalent antibodies and uses therefor
TWI316088B (en) Anti-tnf alpha antibodies and their uses
GB0029360D0 (en) Humanised antibodies and uses thereof
IL225633A0 (en) Anti-alpha-v-beta - 6 antibodies and uses thereof
EP1551447A4 (en) Anti-addl antibodies and uses thereof
IL154325A (en) Isolated anti-il-12 antibody and composition comprising the same
GB9927332D0 (en) Novel antibody and uses thereof
HUP0400697A3 (en) Silensed anti-cd28 antibodies and use thereof
IL156161A0 (en) Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
GB0007333D0 (en) Novel compounds and their manufacture and use
AU2003219093A8 (en) Anti-hpv-16 e7 antibodies and their use
EP1589033A4 (en) Antibody and use thereof
IL166063A0 (en) Antibodies and uses thereof
GB0026134D0 (en) Peptides and their use
EP1302770A4 (en) Particle-labeled protein and immuno-chromatograph using the same
GB0021497D0 (en) Compounds and their use
GB0007530D0 (en) Trityl-type compounds and their use
EP1627888A4 (en) Antibody and use thereof
EP1437367A4 (en) Antibody and use thereof
GB0005071D0 (en) Antibodies
GB0003527D0 (en) Antibodies
GB0227080D0 (en) Antibodies and uses thereof
GB0002559D0 (en) Virulencegene and protein and their use
GB0016824D0 (en) Human monoclonal antibodies
GB0017139D0 (en) Human monoclonal antibodies

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)